The results of the ODYSSEY OUTCOMES trial reported that among patients with recent acute coronary syndromes, alirocumab independently reduced cardiovascular events by lowering Lp(a), and cardiovascular events were predicted to be reduced by 2.5% with a 5-mg/dl reduction in Lp(a) levels [38]. Here, LPA is linked to acute coronary syndrome.